financetom
Business
financetom
/
Business
/
Why Aptevo Therapeutics Stock Is Cratering
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Why Aptevo Therapeutics Stock Is Cratering
Apr 11, 2024 12:32 PM

Aptevo Therapeutics Inc. ( APVO ) shares are trading lower Thursday after the company priced its $4.6 million public offering.

The Details:

Aptevo announced the pricing of a public offering of 3,400,000 shares of its common stock or pre-funded warrants in lieu thereof and warrants to purchase up to an aggregate of 6,800,000 shares of its common stock at a purchase price of $1.35 per share.

Aptevo shares are dropping on heavy trading volume. According to data from Benzinga Pro, more than 3.8 million shares have been traded in the session, compared to the stock’s 100-day average of slightly more than 138,000 shares.

Related News: What’s Going On With Chinese EV Stocks Nio And XPeng?

APVO Stock Prediction 2024:

Equity research analysts on and off Wall Street typically use earnings growth and fundamental research as a form of valuation and forecasting. But many in trading turn to technical analysis as a way to form predictive models for share price trajectory.

Some investors look to trends to help forecast where they believe a stock could trade at a certain point in the future. Looking at Aptevo Therapeutics ( APVO ), an investor could make an assessment about a stock's long term prospects using a moving average and trend line. If they believe a stock will remain above the moving average, which many believe is a bullish signal, they can extrapolate that trend into the future using a trend line. For Aptevo Therapeutics ( APVO ), the 200-day moving average sits at $16.38, according to Benzinga Pro, which is above the current price of $1.05. For more on charts and trend lines, see a description here.

Traders believe that when a stock is above its moving average, it is a generally bullish signal, and when it crosses below, it is a more negative signal. Investors could use trend lines to make an educated guess about where a stock could trade at a later date if conditions remain stable.

APVO Price Action: According to Benzinga Pro, Aptevo Therapeutics ( APVO ) shares are down by more than 59% at $0.98 at the time of publication Thursday.

Image: james-yarema from Unsplash

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BMO Down 2.4% in US Premarket on Mixed Q4 Results; Lifts Dividend and Announces Buyback
BMO Down 2.4% in US Premarket on Mixed Q4 Results; Lifts Dividend and Announces Buyback
Dec 5, 2024
06:34 AM EST, 12/05/2024 (MT Newswires) -- Bank of Montreal ( BERZ ) (BMO.TO, BMO) was at last look down 2.4% in US premarket trade on Thursday after reporting mixed fourth-quarter earnings. The bank still lifted its dividend and said it will repurchase up to 20 million of its common shares. Net income rose to $2,304 million on the quarter...
GMS Fiscal Q2 Adjusted Earnings Drop, Sales Rise
GMS Fiscal Q2 Adjusted Earnings Drop, Sales Rise
Dec 5, 2024
06:34 AM EST, 12/05/2024 (MT Newswires) -- GMS (GMS) reported fiscal Q2 adjusted net income Thursday of $2.02 per diluted share, down from $2.40 a year earlier. Analysts polled by FactSet expected $2.19. Net sales for the fiscal quarter ended Oct. 31 was $1.47 billion, up from $1.42 billion a year earlier. Analysts surveyed by FactSet expected $1.46 billion. GMS...
Synopsys Issues Downbeat Full-Year Revenue Outlook Despite Fiscal Fourth-Quarter Beat
Synopsys Issues Downbeat Full-Year Revenue Outlook Despite Fiscal Fourth-Quarter Beat
Dec 5, 2024
06:35 AM EST, 12/05/2024 (MT Newswires) -- Synopsys ( SNPS ) shares dropped early Thursday as the software company issued a downbeat full-year revenue outlook despite reporting fiscal fourth-quarter results above Wall Street's expectations. The company anticipates per-share adjusted earnings to be in a range of $14.88 to $14.96 and revenue between $6.75 billion and $6.81 billion for fiscal 2025....
Exclusive-HSBC appoints Lisa McGeough to lead US as CEO Elhedery shuffles leaders
Exclusive-HSBC appoints Lisa McGeough to lead US as CEO Elhedery shuffles leaders
Dec 5, 2024
NEW YORK (Reuters) - HSBC ( HSBC ) promoted Lisa McGeough to become its president and CEO for the United States at the start of next year, the bank said on Thursday in a statement first seen by Reuters. The appointment comes as part of a sweeping overhaul by new CEO Georges Elhedery, who has made a raft of leadership...
Copyright 2023-2026 - www.financetom.com All Rights Reserved